خانه › سرطان ریه غیرسلول کوچک › ایندیانا › Indianapolis
آزمایش‌های بالینی سرطان ریه غیرسلول کوچک در Indianapolis، IN
32 مطالعه برای سرطان ریه غیرسلول کوچک در مراکز Indianapolis (در شعاع حدود ۳۰ مایل) در جستجوی شرکت‌کننده هستند. یک مطالعه را باز کنید تا شرایط شرکت و نحوه تماس با تیم پژوهشی را ببینید.
متن رسمی مطالعه (انگلیسی)
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
در حال جذب شرکت‌کنندهمرحله 3
- Saint Catherine Hospital, Indianapolis
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
در حال جذب شرکت‌کنندهمرحله 3
- Saint Catherine Hospital, Indianapolis
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
در حال جذب شرکت‌کنندهمرحله 1
- IU Simon Cancer Center, Indianapolis
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
در حال جذب شرکت‌کنندهمرحله 3
- Franciscan Health ( Site 0219), Indianapolis
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
در حال جذب شرکت‌کنندهمرحله 1
- Exelixis Clinical Site #4, Indianapolis
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
در حال جذب شرکت‌کنندهمرحله 3
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- Sidney and Lois Eskenazi Hospital, Indianapolis
- IU Health West Hospital, Avon · 13 مایل فاصله
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
در حال جذب شرکت‌کنندهمرحله 1
- Indiana University Simon Comprehensive Cancer Center, Indianapolis
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
در حال جذب شرکت‌کنندهمرحله 3
- Community Health Network, Inc, Indianapolis
- Community Health Network, Inc., Indianapolis
- Community Health Network, Inc., Indianapolis
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
در حال جذب شرکت‌کنندهمرحله 3
- Franciscan Health, Indianapolis
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
در حال جذب شرکت‌کنندهمرحله 2/3
- Indiana University Health University Hospital, Indianapolis
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
در حال جذب شرکت‌کنندهمرحله 1/2
- Indiana University (IU) Health - Multi-D Oncology Clinic, Indianapolis
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
در حال جذب شرکت‌کنندهمرحله 1/2
- Community Health Network, Indianapolis
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
در حال جذب شرکت‌کنندهمرحله 3
- Clinical Study Site, Indianapolis
Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
در حال جذب شرکت‌کنندهمرحله 2
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
در حال جذب شرکت‌کنندهمرحله 3
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
- Franciscan Health, Indianapolis
- Community Cancer Center North, Indianapolis
A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer
در حال جذب شرکت‌کنندهمرحله 1
- Community Health Network, Indianapolis
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
در حال جذب شرکت‌کنندهمرحله 1
- Community Health Network, Indianapolis
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
در حال جذب شرکت‌کنندهمرحله 1
- Community Health Network, Inc, Indianapolis
- Community Health Network, Inc., Indianapolis
- Community Health Network Investigational Drug Services, Indianapolis
- و 1 مورد دیگر
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
در حال جذب شرکت‌کنندهمرحله 3
- Franciscan Health Indianapolis, Indianapolis
A Study of LY4175408 in Participants With Advanced Cancer
در حال جذب شرکت‌کنندهمرحله 1
- Community Health Network, Indianapolis
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
در حال جذب شرکت‌کنندهمرحله 1
- Community Health Network, Inc. /ID# 243011, Indianapolis
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
در حال جذب شرکت‌کنندهمرحله 2
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
در حال جذب شرکت‌کنندهمرحله 2/3
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- Richard L. Roudebush Veterans Affairs Medical Center, Indianapolis
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
در حال جذب شرکت‌کنندهمرحله 2
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
در حال جذب شرکت‌کنندهمرحله 2
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
A Study of VET3-TGI in Patients With Solid Tumors
در حال جذب شرکت‌کنندهمرحله 1
- Community Health Network, Indianapolis
Repositioning Immunotherapy in VetArans With Lung Cancer
در حال جذب شرکت‌کنندهمرحله 2
- Richard L. Roudebush VA Medical Center, Indianapolis, IN, Indianapolis
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
در حال جذب شرکت‌کنندهمرحله 1/2
- Research Site, Indianapolis
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
در حال جذب شرکت‌کننده
- Richard L. Roudebush VA Medical Center, Indianapolis, IN, Indianapolis
GEMINI-NSCLC: NSCLC Biomarker Study
در حال جذب شرکت‌کنندهمطالعه مشاهده‌ای
- Community Health Network, Indianapolis
Evaluating a Fasting-mimicking Diet in Combination With Immunotherapy in Patients With Non-small Cell Lung Cancer
در حال جذب شرکت‌کننده
- Richard L. Roudebush VA Medical Center, Indianapolis, IN, Indianapolis
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
در حال جذب شرکت‌کنندهمرحله 1/2
- Community Health Network, Inc., Indianapolis
آزمایش‌های سرطان ریه غیرسلول کوچک در سایر شهرها
- Houston, TX145 مطالعه
- New York City, NY121 مطالعه
- Arlington, VA104 مطالعه
- Nashville, TN97 مطالعه
- Boston, MA90 مطالعه
- Los Angeles, CA87 مطالعه
- St. Louis, MO73 مطالعه
- Chicago, IL61 مطالعه
- Baltimore, MD60 مطالعه
- San Antonio, TX59 مطالعه
- Columbus, OH57 مطالعه
- Washington, DC55 مطالعه
سایر مطالعات در Indianapolis
- سرطان (همه انواع)24 مطالعه
- نارسایی قلبی23 مطالعه
- چاقی20 مطالعه
- سرطان پستان20 مطالعه
- سرطان متاستاتیک19 مطالعه
- سرطان کولورکتال18 مطالعه
- سرطان تخمدان17 مطالعه
- بیماری قلبی-عروقی17 مطالعه
- سرطان ریه16 مطالعه
- دیابت نوع ۱14 مطالعه
- سرطان آندومتر14 مطالعه
- بیماری آلزایمر14 مطالعه
از ClinicalTrials.gov، داده‌ها در تاریخ 6 اکتبر 2026 دریافت شده است. هر مطالعه شرایط اختصاصی خود را دارد؛ تیم پژوهشی تصمیم می‌گیرد چه کسانی می‌توانند شرکت کنند.